Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog
January 09 2012 - 1:14AM
Zacks
Several biotech companies we cover at Zacks Investment Research
are attending the series of healthcare conferences this week in San
Francisco. These conferences include the JP Morgan Healthcare
Conference, OneMed Forum, and Biotech Showcase.
Companies are attending include Advaxis (ADXS),
Bio-Path Holdings Inc. (BPTH), CytRx Corp (CYTR), EpiCept Corp
(EPCT), Galena Biopharma (GALE), ImmunoCellular Biotherapeutics
(IMUC), NeoGenomics (NGNM), Northwest Biotherapeutics (NWBO),
andPressure BioSciences (PBIO).
These biotech companies are covered by Zacks Small Cap Research
team. Following are the investment highlights for each company.
Full research reports can be obtained from our sales team.
Advaxis Inc. (ADXS)
Advaxis is a Listeria based immunotherapy company focused on the
development of immunotherapeutics for cancer treatment. We are
optimistic about the Company’s unique Listeria platform technology
which holds advantages over its peers. The Company’s lead drug
candidate ADXS11-001 is in Phase II clinical trials for the
treatment of cervical cancer and cervical dysplasia. Another Phase
II trial will be initiated for the treatment of head and neck
cancer soon. Other pipeline candidates target breast, brain and
prostate cancer. We believe Advaxis is heading in the right
direction.
Bio-Path Holdings Inc. (BPTH)
Bio-Path is a development stage drug delivery biotech
company. We are optimistic about the great potential of the
Company’s neutral lipid drug delivery technology and
ligand-enhanced lipid tumor targeting technology, which enable
systemic delivery of antisense, RNAi and siRNA drug candidates.
Bio-Path’s pipeline targets the multi-billion dollar cancer market
and the Company has moved its lead drug candidate liposomal-Grb-2
into a Phase I trial. The Company’s good working relationship with
the MD Anderson Cancer Center and its out-license oriented strategy
should build shareholder value in a rapid and cost-effective
way.
CytRx Corp (CYTR)
CytRx is a biopharmaceutical company with a focus on oncology. The
Company has three candidates in middle to late stage development
targeting various cancer indications. The most advanced candidate
is tamibarotene which is in a pivotal clinical trial for acute
promyelocytic leukemia (APL). The combined market opportunity for
CytRx’s pipeline is huge. The Company’s strategy is to develop
drugs with known mechanisms of action which will minimize
operational risks. CytRx is well capitalized with a strong balance
sheet which sets it apart from its peers. Current valuation is low
based on the Company’s fundamentals. Therefore, we assign a market
Outperform rating on CytRx.
EpiCept Corp (EPCT)
EpiCept is a commercial stage specialty pharmaceutical company
targeting large cancer and pain markets. The Company’s lead cancer
candidate Ceplene has been already approved in EU and Israel for
the remission maintenance of AML and a pivotal trial for Ceplene is
planned in the US. The Company’s other candidates include AmiKet
for peripheral neuropathy, Azixa and Crolibulin for cancers which
are all in Phase II trials. We are optimistic about EpiCept’s
prospect. Current valuation is low and we see a great potential for
appreciation in share price as the Company continues to advance its
pipeline and boosts its balance sheet.
Galena Biopharma (GALE)
Galena has been transformed into a late stage development biotech
company through its acquisition of Apthera. The Company is focused
on cancer vaccines. Lead drug candidate NeuVaxTM has demonstrated
excellent efficacy data and safety profile for breast cancer
patients in Phase II trials and will enter into a Phase III trial
in the first half of 2012. Newly acquired cancer vaccine FBP
targets gynecological cancers and is going to enter into the clinic
in 1H2012. Galena has a relatively strong balance sheet. Current
valuation is low based on the Company’s strong fundamentals. We
have an Outperform rating on Galena.
ImmunoCellular Biotherapeutics
(IMUC)
IMUC is a clinical stage biotech company focused on the research
and development of innovative cancer therapeutics. The Company’s
lead drug candidate ICT-107 is next generation cancer vaccine
targeting cancer stem cells to prevent recurrence. ICT-107 has
demonstrated best clinical data for glioblastoma so far and is
under a Phase II trial. ICT-107 holds a high promise for
glioblastoma and has potential for other cancers. IMUC also has a
pipeline based on its off-the-shelf peptide vaccine technology and
monoclonal antibody technology which ensures sustainable growth of
the Company. IMUC is heading in the right direction and poised to
deliver shareholder value.
NeoGenomics (NGNM)
NeoGenomics is a pure play cancer genetics testing lab with
competitive advantages. The Company’s industry leading turn-around
times, unique tech-only business model, state of the art lab
information system, and extensive client education programs are key
factors to attract clients.
Total revenue will grow at 25.6% CAGR from 2010 to 2015. Meanwhile,
increased operating leverage will ultimately contribute to the
bottom line. The Company will turn profitable in 4Q2011 and EPS
will grow to $0.17 per share in 2015.
We rate NGNM shares Outperform based on the Company’s strong
fundamentals.
Northwest Biotherapeutics (NWBO)
Northwest Biotherapeutics is a late clinical stage biotech company
engaged in the development of cell based cancer
immunotherapeutics. We are optimistic with the Company’s
dendritic cell-based platform technology and its lead program
DCVax-L for glioblastoma multiform, which is in a Phase II clinical
trial designed and powered as a pivotal trial. Another late stage
program is DCVax-Prostate. The Company is looking for a partner to
initiate Phase III trials of this program due to scale of resources
required for the Phase III trials.
Both DCVax-L and DCVax-Prostate have the potential to become
blockbusters if approved in our view. NWBO has established an
unusually deep pipeline. Its DCVax-Direct technology can target
almost every solid tumor. Current targets include liver, head &
neck, ovarian and pancreatic cancers.
Progress has been made in the past few months in terms of clinical
trials, business development and balance sheet strengthening.
Current valuation is attractive and upside potential is high at
current price level.
Pressure BioSciences (PBIO)
Pressure BioSciences (PBIO) is a research products and services
provider for the life science industry. We are impressed and
optimistic about the Company’s novel, enabling platform technology:
pressure cycling technology (PCT), which has competitive advantages
over existing technologies in the sample preparation market.
PBIO operates in the multi-billion dollar but underserved research
products and services market with a current focus on sample
preparation for life science research. The research products and
services market is a rapidly growing market with a large and
immediate need for better technology, which we expect will create a
huge opportunity for PBI to grow its business in the coming
years.
Based upon the PCT platform, PBIO has established a broad product
portfolio for the sample preparation market. The instruments and
consumables, a “razor and blade” model, that form its PCT Sample
Preparation System (PCT SPS) are now increasingly being recognized
by many research labs as a novel and paradigm shifting sample
preparation method due to PBI’s focused marketing efforts. We
believe uptake of the PCT SPS will accelerate in the coming
years.
PCT is increasingly gaining recognition by research labs and user
adoption will accelerate in the coming years due to the focused
marketing efforts by the Company.
Current price is undervalued compared to its peers in our view. We
encourage investors to accumulate PBI’s shares at the current
level.
Please email scr@zacks.com with the ticker as the subject
to request a free copy of the full research report
on any company mentioned above.
ADVAXIS INC (ADXS): Free Stock Analysis Report
BIO-PATH HLDGS (BPTH): Free Stock Analysis Report
CYTRX CORP (CYTR): Free Stock Analysis Report
EPICEPT CORP (EPCT): Free Stock Analysis Report
GALENA BIOPHARM (GALE): Free Stock Analysis Report
IMMUNOCELLULAR (IMUC): Free Stock Analysis Report
NEOGENOMICS INC (NGNM): Free Stock Analysis Report
NORTHWEST BIOTH (NWBO): Free Stock Analysis Report
PRESSURE BIOSCI (PBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024